YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer

Yun, J; Hong, MH; Kim, SY; Park, CW; Kim, S; Yun, MR; Kang, HN; Pyo, KH; Lee, SS; Koh, JS; Song, HJ; Kim, DK; Lee, YS; Oh, SW; Choi, S; Kim, HR; Cho, BC

Kim, HR (reprint author), Yonsei Univ, Yonsei Canc Res Inst, Coll Med, Seoul, South Korea.; Kim, HR (reprint author), Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea.; Cho, BC (reprint author), Yonsei Univ, Coll

CLINICAL CANCER RESEARCH, 2019; 25 (8): 2575

Abstract

Purpose: Given that osimertinib is the only approved third-generation EGFR-TKI against EGFR activating and resistant T790M mutated non-small cell lung......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索